Compare WVE & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WVE | ARQT |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | 2015 | 2020 |
| Metric | WVE | ARQT |
|---|---|---|
| Price | $6.19 | $21.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 6 |
| Target Price | $29.81 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 3.9M | 2.1M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | N/A | ★ N/A |
| Revenue | $3,704,000.00 | ★ $376,072,000.00 |
| Revenue This Year | N/A | $34.85 |
| Revenue Next Year | $85.67 | $29.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 149.43 | 91.34 |
| 52 Week Low | $5.02 | $12.72 |
| 52 Week High | $21.73 | $31.77 |
| Indicator | WVE | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 35.45 | 46.11 |
| Support Level | $6.02 | $21.12 |
| Resistance Level | $7.65 | $21.84 |
| Average True Range (ATR) | 0.35 | 0.98 |
| MACD | 0.05 | 0.13 |
| Stochastic Oscillator | 15.04 | 61.97 |
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.